公开(公告)号：US20180185365A1

公开(公告)日：2018-07-05

申请号：US15879942

申请日：2018-01-25

Applicant: Novartis AG

Inventor： Fang LI ,  Hui-Qin Wang ,  Ensar Halilovic ,  Jinsheng Liang

IPC: A61K31/506 ,  A61K31/496 ,  A61K31/435 ,  A61K31/404 ,  A61K31/4025 ,  A61K45/06

CPC classification number: A61K31/506 ,  A61K31/4025 ,  A61K31/404 ,  A61K31/435 ,  A61K31/496 ,  A61K45/06 ,  A61K2300/00

Abstract: A pharmaceutical combination comprising (a) an ALK inhibitor, or a pharmaceutically acceptable salt thereof, and (b) at least one HDMA-2/p53 receptor inhibitor or a pharmaceutically acceptable salt, or at least one BRaf inhibitor or a pharmaceutically acceptable salt, and optionally a pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of cancer; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

公开(公告)号：US20170143723A1

公开(公告)日：2017-05-25

申请号：US15423855

申请日：2017-02-03

Applicant: Novartis AG

Inventor： Stephane Ferretti ,  Sebastien Jeay ,  Ensar Halilovic ,  Fang LI ,  Hui-Qin Wang

IPC: A61K31/519 ,  A61K31/496 ,  A61K31/506

CPC classification number: A61K31/519 ,  A61K31/4188 ,  A61K31/496 ,  A61K31/505 ,  A61K31/506 ,  A61K2300/00

Abstract: The disclosure relates to a pharmaceutical combination of a mdm2/4 inhibitor, namely (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one or (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one, and a cyclin dependent kinase 4/6 (CDK4/6) inhibitor 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide. In addition, the disclosure relates to a pharmaceutical combination product. The disclosure also relates to corresponding pharmaceutical formulations, uses and treatment methods comprising said mdm2/4 inhibitor or a cyclin dependent kinase 4/6 (CDK4/6) inhibitor.

公开(公告)号：US20220241277A1

公开(公告)日：2022-08-04

申请号：US17714996

申请日：2022-04-06

Applicant: Novartis AG ,  The General Hospital Corporation

Inventor： Leila DARDAEI ALGHALANDIS ,  Jeffrey Adam ENGELMAN ,  Huaixiang HAO ,  Matthew J. LAMARCHE ,  Fang LI ,  Hui-Qin WANG

IPC: A61K31/506 ,  A61P35/00 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377

Abstract: A pharmaceutical combination comprising an ALK inhibitor, in free form or a pharmaceutically acceptable salt thereof, and a SHP2 inhibitor, in free form or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

公开(公告)号：US20190134033A1

公开(公告)日：2019-05-09

申请号：US16180078

申请日：2018-11-05

Applicant: Novartis AG

Inventor： Fang LI ,  Hui-Qin WANG ,  Ensar HALILOVIC ,  Jinsheng LIANG

IPC: A61K31/506 ,  A61K31/496 ,  A61K31/435 ,  A61K45/06 ,  A61K31/4025 ,  A61K31/404

Abstract: A pharmaceutical combination comprising (a) an ALK inhibitor, or a pharmaceutically acceptable salt thereof, and (b) at least one HDMA-2/p53 receptor inhibitor or a pharmaceutically acceptable salt, or at least one BRaf inhibitor or a pharmaceutically acceptable salt, and optionally a pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of cancer; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.